Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca Zibotentan Phase III Study 14 fails to meet primary endpoint
Zibotentan is a novel once daily tablet and works by blocking the endothelin pathway. The Phase III study assessed Zibotentan 10mg added to standard of care treatment in
Zibotentan is a novel once daily tablet and works by blocking the endothelin pathway. The Phase III study assessed Zibotentan 10mg added to standard of care treatment in
According to the CHMP, the benefits from using the drug to treat MS did not justify its risks. Recently, Merck’s MS pill got Austrailian and Russian approval and
NextPharma claims that its Belgian site, Braine-l’Alleud, has extensive know how in aseptic production and packaging including the manufacture of cytotoxic products (lyophilization and solutions) gained over more
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of Tasigna in the indication based on a pivotal Phase III clinical trial in which Tasigna surpassed
Erin Ascher will be responsible for leading Omnicare’s human resources function, including designing and implementing strategies in the areas of attracting, retaining, developing and rewarding employees. Before joining
The trial will evaluate the value of genetic testing on reducing adverse events associated with Warfarin therapy. GenMark, a provider of automated, multiplex molecular diagnostic testing systems, said
Horizons-AMI trial was sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and The Medicines Company. Horizons-AMI is a randomised trial to compare the
Amgen said that the lamellae result from the interaction of the formulation with glass vials over the shelf life of the product. Epogen and Procrit are indicated for
As per the extended agreement, Wyeth’s commercialisation efforts in the US is expected to continue through 31 December 2010, and may be extended at Progenics’ option to 31
According to Progenika Biopharma, the diagnostic test rapidly diagnoses patients with complete and partial lipoprotein lipase deficiency (LPLD) and has been developed under an agreement with Amsterdam Molecular